

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Obicetrapib and obicetrapib–ezetimibe for treating primary  
hypercholesterolaemia or mixed dyslipidaemia [ID6519]**

**Final Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>Menarini (obicetrapib, obicetrapib–ezetimibe)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>Blood Pressure UK</li> <li>Cardiac Risk in the Young</li> <li>Cardiovascular Care Partnership</li> <li>Circulation Foundation</li> <li>Gene People</li> <li>Genetic Alliance UK</li> <li>HEART UK</li> <li>Metabolic Support UK</li> <li>Pulmonary Hypertension Association UK</li> <li>Pumping Marvellous Foundation</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Stroke Association</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>Association of Genetic Nurses &amp; Counsellors</li> <li>British &amp; Irish Hypertension Society</li> <li>British and Irish Association of Stroke Physicians</li> <li>British Association for Nursing in Cardiovascular Care</li> <li>British Association of Endocrine and Thyroid Surgeons</li> <li>British Atherosclerosis Society</li> <li>British Cardiovascular Society</li> <li>British Dietetic Association</li> <li>British Geriatrics Society</li> <li>British Heart Foundation</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health - Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>NHS Wales Joint Commissioning Committee</li> <li>Scottish Medicines Consortium</li> <li>Welsh Government</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>Amarox (atorvastatin, rosuvastatin)</li> <li>Amgen (evolocumab)</li> <li>Aspire Pharma (fluvastatin)</li> <li>AstraZeneca (rosuvastatin)</li> <li>Aurobindo Pharma - Milpharm (atorvastatin, ezetimibe, pravastatin, rosuvastatin, simvastatin)</li> <li>Biocon Pharma (rosuvastatin)</li> <li>Brown &amp; Burk (atorvastatin, rosuvastatin, simvastatin)</li> <li>Daiichi Sankyo (bempedoic acid)</li> <li>Dr. Reddy's Laboratories (atorvastatin)</li> <li>Flamingo Pharma (atorvastatin)</li> <li>Glenmark Pharmaceuticals Europe (ezetimibe, rosuvastatin)</li> </ul>

Final stakeholder list for the evaluation of obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519

Issue date: January 2026

© National Institute for Health and Care Excellence 2026. All rights reserved. 1 of 3

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>British Inherited Metabolic Disease Group</li> <li>British Nuclear Cardiology Society</li> <li>British Society for Gene and Cell Therapy</li> <li>British Society for Genetic Medicine</li> <li>British Society for Haematology</li> <li>British Society for Haemostasis and Thrombosis</li> <li>British Society for Heart Failure</li> <li>British Society for Paediatric Endocrinology and Diabetes</li> <li>British Society of Cardiovascular Imaging</li> <li>British Thoracic Society</li> <li>Clinical Leaders of Thrombosis</li> <li>National Heart and Lung Institute</li> <li>National Metabolic Biochemistry Network</li> <li>Neonatal and Paediatric Pharmacy Group</li> <li>Primary Care Cardiovascular Society</li> <li>Royal College of Emergency Medicine</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Paediatrics and Child Health</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society for Cardiological Science &amp; Technology</li> <li>Society for Endocrinology</li> <li>Society for Vascular Technology of Great Britain and Ireland</li> <li>Society of Vascular Nurses</li> <li>UK Clinical Pharmacy Association</li> <li>Vascular Society of Great Britain &amp; Ireland</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	<ul style="list-style-type: none"> <li>Krka (atorvastatin, ezetimibe, rosuvastatin)</li> <li>MSN Laboratories Europe (atorvastatin, rosuvastatin)</li> <li>Mylan (atorvastatin)</li> <li>Novartis pharmaceuticals (inclisiran)</li> <li>Novumgen (rosuvastatin)</li> <li>Organon Pharma (ezetimibe, simvastatin)</li> <li>Rivopharm (ezetimibe)</li> <li>Rosemont Pharmaceuticals (atorvastatin, simvastatin)</li> <li>Sandoz (atorvastatin, ezetimibe, fluvastatin, rosuvastatin, simvastatin)</li> <li>Sanofi (alirocumab)</li> <li>Sun Pharmaceuticals (atorvastatin, rosuvastatin, simvastatin)</li> <li>Thame Laboratories (rosuvastatin)</li> <li>Zentiva (atorvastatin, ezetimibe, rosuvastatin)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>British Society for Cardiovascular Research</li> <li>Cardiac and Cardiology Research Department, Barts</li> <li>Cochrane Heart, Stroke and Circulation Thematic Group</li> <li>Cochrane Metabolic &amp; Endocrine Disorders Group</li> <li>European Council for Cardiovascular Research</li> <li>Genomics England</li> <li>Heart Research UK</li> <li>MRC Clinical Trials Unit</li> <li>National Centre for Cardiovascular Preventions and Outcomes</li> <li>National Institute for Health &amp; Care Research</li> <li>Wellcome Trust</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.